MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2023 International Congress

    Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain

    I. Muro Garcia, J. Alonso Maroto, B. Gonzalez Garcia, E. Carabajal Pendon, E. Casas, L. Lopez Manzanares (Madrid, Spain)

    Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…
  • 2023 International Congress

    The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson’s disease patients

    O. Phokaewvarangkul, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the plasma level of vitamin B and homocysteine between PD patients with conventional medications and PD patients with CSAI. Background: Although levodopa…
  • 2022 International Congress

    Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    O. Rascol, W. Poewe, F. Stocchi, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Toulouse, France)

    Objective: Evaluate safety and tolerability of apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease…
  • 2022 International Congress

    Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

    Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…
  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • 2022 International Congress

    Expanding the armamentarium of clinical use of apomorphine in movement disorders.

    S. Bansal, JR. Chai, M. Jog (London, Canada)

    Objective: To demonstrate the use of subcutaneous(SC) apomorphine injections in suspected untreated dopamine responsive conditions. Background: Apomorphine is a dopamine agonist historically used in dopamine…
  • 2022 International Congress

    Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

    S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

    Objective: Evaluate magnitude of motor improvement with increasing doses of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease (PD) and OFF episodes. Background: Identifying…
  • 2022 International Congress

    Use of apomorphine infusion pump in the elderly population : a 5 years follw up study on efficacy, safety and tolerability in a cohort bases study

    C. Borrue- Fernandez, M. Mata, C. Jimeno, M. Almarcha (San Sebastian Reyes, Spain)

    Objective: Evaluate the efficacy, tolerability and safety of subcutaneous apomorphine infusion in elderly patients with advanced Parkinson's disease in a five years follow up cohort. Background: Continuous infusion by subcutaneous apomorphine pump has…
  • 2022 International Congress

    May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

    A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

    Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley